In the Interim...

Berry
  • 5,0 (15)
  • TOÁN HỌC
  • HẰNG TUẦN

A podcast on statistical science and clinical trials. Explore the intricacies of Bayesian statistics and adaptive clinical trials. Uncover methods that push beyond conventional paradigms, ushering in data-driven insights that enhance trial outcomes while ensuring safety and efficacy. Join us as we dive into complex medical challenges and regulatory landscapes, offering innovative solutions tailored for pharma pioneers. Featuring expertise from industry leaders, each episode is crafted to provide clarity, foster debate, and challenge mainstream perspectives, ensuring you remain at the forefront of clinical trial excellence.

  1. 4 NGÀY TRƯỚC

    A Visit with Michael Harhay

    In this episode of "In the Interim…", Dr. Scott Berry speaks with Dr. Michael Harhay, Associate Professor at the University of Pennsylvania and Director of the Center for Clinical Trials Innovation. The conversation explores Dr. Harhay’s progression through neuroscience, philosophy, epidemiology, and statistics, examining how this academic path shapes his work in clinical trial methodology. They discuss the Center’s role in addressing unresolved methodological questions arising from pragmatic, health system-based trials, including challenges with cluster and factorial randomized designs. The episode focuses on statistical and conceptual issues in endpoint selection for critical care, such as the analysis of informatively truncated outcomes, composite endpoints including organ support-free days, and the application of the win ratio. The increasing use of Bayesian methods in trial design is addressed. Key Highlights Dr. Harhay’s academic background and transition into clinical trial methodology at Penn.The mission of the Center for Clinical Trials Innovation to support methodologic research and training, particularly among statisticians participating in multi-center health system trials.Discussion of hospital-level and provider-level randomization strategies in cluster and factorial designs within health systems.Ongoing challenges in analysis of composite and informatively truncated endpoints, especially in critical care, exemplified by ventilator-free and organ support-free days.Evaluation of analytic strategies including survival average causal effect, composite endpoints, and the win ratio, with emphasis on the need for clinical rather than purely statistical weighting of outcomes.Consideration of the conceptual strengths of Bayesian methods and their integration into modern trial design and decision analysis.For more, visit us at https://www.berryconsultants.com/

    39 phút

  2. 26 THG 1

    The FDA Bayesian Guidance

    In this episode of "In the Interim…", Dr. Scott Berry and Dr. Kert Viele deliver a quick reaction to the FDA’s draft guidance on Bayesian statistics for clinical trials of drugs and biologics. Their assessment addresses the structure, content, and impact of the document, emphasizing evidence-based requirements and guidance scope. The episode breaks down regulatory language, technical expectations, and workflow implications for clinical trial sponsors and statisticians. Key Highlights Clear distinction between trials justified by type 1 error control and trials justified by agreement on Bayesian priors and decision rule.Explanation of how informative priors can be created based on external or historical data.Technical explanation of dynamic discounting/borrowing, especially in Bayesian hierarchical models for rare populations, pediatric-adult extrapolation, related disease subgroups, and platform and basket trials (e.g., ROAR).In-depth look at the necessity of sensitivity and robustness checks for different priors, and the FDA’s design prior and analysis prior terminology.FDA’s requirements for accepting external data sources: data provenance, patient-level comparability, recency, and appropriate covariate adjustments.Comparison with ICH E20 on adaptive designs, providing context for ongoing regulatory harmonization and possible influence on international regulatory directions.Direct warning against attempts to misuse Bayesian methodology as a substitute for scientific rigor; legitimate uses must meet FDA standards and not simply serve to lower evidentiary bars.Resource:  FDA News Release:  https://www.fda.gov/news-events/press-announcements/fda-issues-guidance-modernizing-statistical-methods-clinical-trials For more, visit us at https://www.berryconsultants.com/

    43 phút

  3. 19 THG 1

    Path 2 Parkinson's Prevention with Drs. Simuni and Wendelberger

    In this episode of "In the Interim…", Dr. Scott Berry is joined by Dr. Tanya Simuni, Arthur C. Nielsen Jr. Professor of Neurology and Director of the Parkinson’s Disease and Movement Disorders Center at Northwestern University, and Dr. Barbara Wendelberger, Senior Statistical Scientist at Berry Consultants. The conversation focuses on the Path to Prevention (P2P) platform trial—an international, multi-arm prevention study in Parkinson’s disease targeting participants defined by biological markers, specifically alpha-synuclein pathology, prior to clinical diagnosis. The discussion covers the PPMI cohort, trial operational and statistical structure, the rationale behind biomarker-driven inclusion, and the use of Bayesian platform trial design. Key Highlights: Parkinson’s disease pathobiology and risk: genotype-phenotype variability, multi-system involvement, and the central roles of age, environment, and genetics.Michael J. Fox Foundation’s PPMI cohort: 4,000+ participants, prospective longitudinal biomarker and clinical data, high participant retention, enabling study of early Parkinson’s.P2P platform structure: multi-arm design, two-stage randomization with shared placebo group, integration of non-randomized PPMI cohort in Bayesian analysis for improved inference.Inclusion criteria: prodromal population biologically defined by CSF alpha-synuclein seed amplification and dopaminergic imaging (DAT-SPECT), highlighting regulatory nuances.Dual primary endpoints: biomarker (DAT-SPECT) and clinical (MDS-UPDRS Part III), 24-36 months follow-up.Commitment to public data sharing in line with the Michael J. Fox Foundation’s open science philosophy.For more, visit us at https://www.berryconsultants.com/

    42 phút

  4. 12 THG 1

    Statistical Communication

    In this episode of “In the Interim…,” host Dr. Scott Berry examines the challenge of communicating complex statistical concepts to non-statistical audiences. Drawing from firsthand experiences in agriculture, professional golf, and clinical development, as well as examples involving historical and scientific figures, Scott reflects on why technical rigor alone often fails to influence. The discussion focuses on the consequences of mismatched language, the importance of empathy, and the utility of simulation when bridging the gap between analysis and stakeholder understanding. Key Highlights Illustrated barriers to statistical communication using stories from farming, golf, and early career encounters.Examples involving John Glenn, Ada Lovelace, and Charles Babbage show how communication, not just science, determines impact.Insights from Alan Alda on empathy as a foundational tool for scientists presenting technical ideas.Clinical trial simulations revealed knowledge gaps—such as misunderstanding of power—when communicating with decision-makers.Emphasizes the necessity of translating analytic outputs into operational, financial, or clinical language for meaningful impact.For more, visit us at https://www.berryconsultants.com/

    42 phút

  5. 29/12/2025

    The Rumor of One Trial for Substantial Evidence

    In this episode of "In the Interim…", host Dr. Scott Berry and frequent co-host Dr. Kert Viele, Senior Statistical Scientist at Berry Consultants, analyze the potential shift in FDA regulatory policy from requiring two independent trials to accepting a single trial as sufficient for “substantial evidence” in drug approvals. Reflecting on the statutory and regulatory definitions originating with the 1962 Federal Food, Drug, and Cosmetic Act and 21 CFR 314.126, they dissect current and emerging interpretations, referencing recent statements by Dr. Martin Makary and coverage described in a STAT article. The conversation focuses on the scientific and statistical foundations of the two-trial threshold, challenges with dichotomous results, and how pooled evidence might increase efficiency and rigor. They discuss statistical implications including alpha thresholds, sample size effects, program power, and the consequences for clinical labeling. The episode also introduces Bayesian approaches as a method for integrating totality of evidence. Attention is given to both population breadth and the possible risks of a narrowed evidentiary base under a single-trial standard. Key Highlights Regulatory and historical context of “substantial evidence” since 1962 and current FDA directives.Industry practice: simultaneous Phase III trials, statistical power, and evidentiary replication.Criticism of binary, trial-level significance thresholds; merits of pooling or meta-analysis.Potential efficiency gains and tradeoffs with a more stringent alpha requirement for single trials.Strategic and operational effects on trial design, sample size, and label indications.Bayesian statistical approaches for full evidence integration, discussed as an analytical viewpoint.

    40 phút

  6. 22/12/2025

    Communication for Scientists: A Discussion with Jenny Devenport

    In this episode of "In the Interim…", Dr. Jenny Devenport, Global Head of Methods, Collaboration, and Outreach at Roche, joins Dr. Scott Berry for a detailed discussion on career evolution, statistical culture, and communication in the pharmaceutical industry. Dr. Devenport describes her transition from psychology in New Mexico to statistical leadership in Basel, emphasizing the formative role of early academic mentors and her experience working across the US and Europe. She outlines her current functions in methods development, internal collaboration, and industry outreach, highlighting active engagement with academic and regulatory communities. The episode scrutinizes differences in workplace culture, such as the emphasis on debate and long-term collaboration in Europe, and differences in educational backgrounds among statisticians. The conversation covers practical barriers and slow adoption of Bayesian methods and the importance of communication in the acceptance of futility analyses in pharma, the importance of scale in problem-solving, and the emergence of AI as a tool for statisticians. Dr. Devenport provides pragmatic strategies for statisticians to improve their influence through tailored, audience-specific communication. Key Highlights Dr. Devenport’s academic and geographic move from the US to EuropeResponsibilities in methods development, collaboration, and outreach at RocheContrasts in US and European pharmaceutical statistics culturesMeasured perspective on AI’s effect on statisticians’ responsibilitiesPractical guidance for statisticians on communication and influence

    40 phút

  7. 15/12/2025

    Navigating the Arena: Platform Trials

    In this episode of "In the Interim…", Dr. Scott Berry delivers a metaphoric critique of single-question trial infrastructure through the sports arena analogy, illustrating the cost, patient burden, and data inefficiency of conventional clinical trials. He provides a methodical comparison of traditional trial models and the platform trial approach, clarifying distinctions between platform, basket, and master protocol structures. Through examples from HEALEY ALS, I-SPY 2, PALM (Ebola), REMAP-CAP, RECOVERY, EPAD, GBM AGILE, and Precision Promise, Scott outlines the measurable efficiencies of platform trials: shared control arms, flexible arm addition and removal, reduced placebo exposure, accelerated timelines, and improved statistical inferences. The episode further examines platform trial performance during the COVID-19 pandemic, highlighting  trial adaptability, and the rapid generation of actionable evidence. Scott also addresses failure scenarios, focusing on EPAD Alzheimer’s as a cautionary case in platform sustainability, cost allocation, and initial funding barriers. Listeners will gain a perspective on the operational and statistical design choices governing today’s most innovative clinical studies. Key Highlights Arena analogy applied to delineate clinical research inefficiency.Operational, statistical, and patient-focused efficiencies in platform versus single-question trials.Precision in terminology: platform, basket, and master protocol definitions.Effects of platform trials on speed and scientific rigor.Factors underlying both platform trial successes and failures.For more, visit us at https://www.berryconsultants.com/

    50 phút

  8. 08/12/2025

    Jumping Hurdles: Interim Analyses for Funding Decisions

    In episode 40 of "In the Interim…", Dr. Scott Berry examines the statistical, operational, and behavioral challenges of using interim analyses as triggers for funding in adaptive and seamless Phase II/III clinical trials. The episode presents a typical hypothetical scenario for rare disease drug development, contrasting conventional two-stage development with a seamless design and highlighting efficiency gains in sample size, patient allocation, and trial duration. Scott details the construction of administrative (financial) interim analyses, underscoring their distinction from futility analyses and their role in funding decisions when complete funding is not secured upfront. He addresses FDA operational bias concerns, emphasizing blinding and limiting information sharing to protect trial integrity. Finally, the episode focuses on developing objective interim funding criteria—using Bayesian predictive probability and assurance—and on leveraging illustrative simulation outputs and sample datasets to bridge the “I’ll know it when I see it” divide between scientists and funders. Practical, empirical, and tailored to real funding barriers in clinical research. Key Highlights Statistical structure and efficiency of seamless Phase II/III trial designsAdministrative (financial) interim analysis setup as funding decision triggers, distinct from futility analysesFDA operational bias guidance and requirements for trial blindingPredictive probability and assurance as objective interim criteriaSample data and simulation outputs to facilitate stakeholder alignmentFor more, visit us at https://www.berryconsultants.com/

    42 phút
Xem tất cả (47)

Xếp Hạng & Nhận Xét

5
/5
15 Xếp hạng

Giới Thiệu

A podcast on statistical science and clinical trials. Explore the intricacies of Bayesian statistics and adaptive clinical trials. Uncover methods that push beyond conventional paradigms, ushering in data-driven insights that enhance trial outcomes while ensuring safety and efficacy. Join us as we dive into complex medical challenges and regulatory landscapes, offering innovative solutions tailored for pharma pioneers. Featuring expertise from industry leaders, each episode is crafted to provide clarity, foster debate, and challenge mainstream perspectives, ensuring you remain at the forefront of clinical trial excellence.

Thông Tin

  • Nhà sáng tạo
    Berry
  • Năm hoạt động
    2025 - 2026
  • Tập
    47
  • Xếp hạng
    Sạch
  • Bản quyền
    © 2025 Berry Consultants
  • Trang web chương trình
    In the Interim...

Có Thể Bạn Cũng Thích